首页> 外文OA文献 >Evaluation of a novel device for the management of high blood pressure and shock in pregnancy in low-resource settings: study protocol for a stepped-wedge cluster-randomised controlled trial (CRADLE-3 trial)
【2h】

Evaluation of a novel device for the management of high blood pressure and shock in pregnancy in low-resource settings: study protocol for a stepped-wedge cluster-randomised controlled trial (CRADLE-3 trial)

机译:低资源环境中妊娠期高血压和休克治疗新设备的评价:阶梯式楔形簇随机对照试验(Cradle-3试验)的研究方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Abstract Background Obstetric haemorrhage, sepsis and pregnancy hypertension account for more than 50% of maternal deaths worldwide. Early detection and effective management of these conditions relies on vital signs. The Microlife® CRADLE Vital Sign Alert (VSA) is an easy-to-use, accurate device that measures blood pressure and pulse. It incorporates a traffic-light early warning system that alerts all levels of healthcare provider to the need for escalation of care in women with obstetric haemorrhage, sepsis or pregnancy hypertension, thereby aiding early recognition of haemodynamic instability and preventing maternal mortality and morbidity. The aim of the trial was to determine whether implementation of the CRADLE intervention (the Microlife® CRADLE VSA device and CRADLE training package) into routine maternity care in place of existing equipment will reduce a composite outcome of maternal mortality and morbidity in low- and middle-income country populations. Methods The CRADLE-3 trial was a stepped-wedge cluster-randomised controlled trial of the CRADLE intervention compared to routine maternity care. Each cluster crossed from routine maternity care to the intervention at 2-monthly intervals over the course of 20 months (April 2016 to November 2017). All women identified as pregnant or within 6 weeks postpartum, presenting for maternity care in cluster catchment areas were eligible to participate. Primary outcome data (composite of maternal death, eclampsia and emergency hysterectomy per 10,000 deliveries) were collected at 10 clusters (Gokak, Belgaum, India; Harare, Zimbabwe; Ndola, Zambia; Lusaka, Zambia; Free Town, Sierra Leone; Mbale, Uganda; Kampala, Uganda; Cap Haitien, Haiti; South West, Malawi; Addis Ababa, Ethiopia). This trial was informed by the Medical Research Council guidance for complex interventions. A process evaluation was undertaken to evaluate implementation in each site and a cost-effectiveness evaluation will be undertaken. Discussion All aspects of this protocol have been evaluated in a feasibility study, with subsequent optimisation of the intervention. This trial will demonstrate the potential impact of the CRADLE intervention on reducing maternal mortality and morbidity in low-resource settings. It is anticipated that the relatively low cost of the intervention and ease of integration into existing health systems will be of significant interest to local, national and international health policy-makers. Trial registration ISCRTN41244132. Registered on 2 February 2016. Prospective protocol modifications have been recorded and were communicated to the Ethics Committees and Trials Committees. The adapted Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Checklist and the SPIRIT Checklist are attached as Additional file 1.
机译:抽象的背景产科出血,败血症和妊高症占全球产妇死亡的50%以上。这些条件的早期发现和有效管理依赖于生命体征。所述Microlife®摇篮生命体征报警(VSA)是一种易于使用的,精确的器件,其测量血压和脉搏。它采用的是提醒医疗服务提供者的各级需要在妇女产科出血,败血症或妊高症护理升级一个红绿灯预警系统,从而协助早期识别血流动力学不稳定和防止产妇死亡率和发病率。该试验的目的是确定实施的摇篮干预(在Microlife®摇篮VSA装置和支架培训包)纳入常规妇幼保健替代现有设备是否会减少在低收入和中等产妇死亡率和发病率的综合结果-income国家的人口。方法托架-3试验是托架干预的台阶楔集群随机对照试验相比常规产妇护理。从常规的孕产妇保健的干预,在2月的间隔超过20个月的过程中交叉(四月2016年至2017年11月)每个集群。确定为怀孕或在产后6周所有的女人,在集群集水区呈现为孕产妇保健有资格参加。哈拉雷,津巴布韦;恩多拉,赞比亚,赞比亚卢萨卡,富顿中心,塞拉利昂;姆巴莱,乌干达主要的结果数据(复合孕产妇死亡,子痫和每10,000交付紧急子宫切除术)在10组(的Gokak,贝尔高姆,印度收集;坎帕拉,乌干达,海地角,海地;西南,马拉维,埃塞俄比亚亚的斯亚贝巴)。这项试验是由医学研究理事会的指导复杂的干预通知。一种方法评估进行了评估在每个站点和成本效益评估将进行实施。该协议的讨论所有方面都在可行性研究进行评估,与干预的后续优化。这项试验将演示摇篮干预对降低资源匮乏的产妇死亡率和发病率的潜在影响。据预计,干预和易于集成到现有的卫生系统的成本相对较低,将是显著感兴趣的地方,国家和国际卫生政策制定者。临床试验注册ISCRTN41244132。注册2月2日2016年预期协议修改已被记录并传送到伦理委员会和试验委员会。适配的标准协议的项目:在介入试验(SPIRIT)建议清单和清单SPIRIT连接作为附加文件1。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号